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Background: Autosomal-dominant polycystic kidney disease (ADPKD) is a hereditary illness that causes renal tubular
epithelial cells to form cysts that proliferate and destroy renal tissue. This usually leads to a decline in renal function,
and often to terminal kidney failure, with need for renal replacement therapy. There is currently no causative therapy.
The mammalian target of rapamycin (mTOR) inhibitor sirolimus (SIR) is an immunosuppressant with strong antiproliferative
effects, and is potentially able to stop or reduce cyst growth and preserve renal function in ADPKD. Continuous mTOR
exposure results in a loss of its antiproliferative effects on renal tubular cells. With a half-life of roughly 60 hours, pulsed
(weekly) administration of SIR may be an effective way to reduce cyst growth and preserve excretory renal function in
ADPKD.
Methods/Design: The Vienna RAP Study is a randomized, double-blind, placebo-controlled trial, funded by the
Anniversary Fund of the Oesterreichische Nationalbank. We will investigate the effects of a weekly dose of 3 mg
SIR on kidney function in 34 patients with advanced ADPKD, compared to a placebo equivalent in 34 patients with
advanced ADPKD, over 24 months. The primary endpoint is creatinine level (less or equal than 1.5-fold increase in
serum creatinine without initiation of dialysis over two years) and dialysis, renal transplantation, or death. The secondary
endpoints are safety, change in proteinuria (as indicated by albumin/creatinine- and protein/creatinine ratio, respectively),
and creatinine clearance.
Discussions: The Vienna RAP Study is, to the best of our knowledge, the first study to investigate the effects of a pulsed
(weekly) dose of SIR on renal function in ADPKD.
Trial registration: This trial was registered with EudraCT (identifier: 2012-000550-60 (EU)) on 27 November 2013 and
with ClinicalTrials.gov (identifier: NCT02055079 (USA)) on 3 February 2014.
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Autosomal-dominant polycystic kidney disease (ADPKD)
is a genetic disorder characterized by uncontrolled prolif-
eration of innumerable macro- and microscopic epithelial-
lined cysts that stem from renal tubular cells. They
compress and destroy renal tissue which leads to a grad-
ual decline in renal function. Other than supportive care,
there is no treatment, and most often renal replacement
therapy by either dialysis or kidney transplantation is ne-
cessary. ADPKD is detected by kidney ultrasound [1-3], or
computed tomography or magnetic resonance imaging.
Depending on whether the mutation is located on the
PKD1 or PKD2 gene, ADPKD 1 or 2 respectively, de-
velops. In the PKD1 mutation, patients usually present in
the third to fourth decade, and renal replacement therapy
usually becomes necessary in the following decade. In the
PKD2 mutation, patients present around the fifth decade,
and often experience a milder course [4]. Effects of the
immunosuppressant sirolimus (SIR) on cyst growth in
ADPKD have been developed in a rodent model with
Han:SPRD rats (Cy/+). SIR applied intraperitoneally leads
to a reduction of overall kidney size, a decrease in cyst
density, and tubular cell proliferation [5]. SIR applied or-
ally reduced worsening of kidney function, cyst prolifera-
tion, cyst volume, and cyst density [6]. mTOR inhibition
(mTOR-I) by either SIR or everolimus (EVER) has been
investigated in preclinical studies and clinical trials but
only subtle, if any, clinically relevant effects on cyst growth
and the preservation of renal function were found [7,8].
Tubular cells, the target of mTOR-I in ADPKD, develop a
resistance towards SIR in vitro as well as in vivo [9]. In a
rodent model of the influence of SIR on the proliferation
of renal tubular cells in acute renal failure, continuous ex-
posure with SIR had a strong anti-proliferative effect
throughout the first three days, which drastically de-
creased throughout the fourth to sixth day. The half max-
imal inhibitory concentration (IC50) of SIR increased
from approximately 10 ng/mL to approximately 100 ng/
mL within a week of exposure. Until now, no study has
accounted for the loss of the strong anti-proliferative ef-
fects of SIR after the fourth day of continuous exposure.
Aim of the trial
The aim of this trial is to disprove the null hypothesis
that pulsed administration of the mTOR-I SIR in a fixed
weekly oral dose of 3 mg compared to placebo does not
preserve excretory renal function in patients with ADPKD
and an estimated glomerular filtration rate (eGFR) below
60 mL/min per 1.73 m2.
Methods/Design
Study design, approval, and registration
The Vienna RAP Study is a randomized, placebo-controlled,
double-blind, single-center trial. Treatment for both activeand placebo groups will be for 24-months duration. The
study is funded with €70,000 provided by the Anniversary
Fund of the Oesterreichische Nationalbank (project grant
number 15170). The study was approved by the Ethics
Commission of the Medical University of Vienna (identify-
ing number 1060/2012). The study was registered at the
Competent Austrian Authorities, Bundesamt für Sicherheit
im Gesundheitswesen (identifying number LCM-718208-
0001), at the European Medicines Agency EudraCT (iden-
tifying number 2012-000550-60), and at the United States
Institute of Health ClinicalTrials.gov (identifying number
NCT02055079).
Participants and site recruitment
Patients with ADPKD and an eGFR (4-variable modifica-
tion of diet in renal disease (MDRD) equation) below
60 mL/min per 1.73 m2 will be included at the out-
patient clinic of the Division of Nephrology and Dialysis,
Department of Medicine III, Medical University of
Vienna by the principal investigator and his representa-
tives. The diagnosis will be confirmed by imaging as
stated above, there will be no discrimination of PKD1 or
PKD2 within the study population. Subjects must sign
the informed consent form to be included in the study.
See Table 1 for inclusion and exclusion criteria. Familial
medical history and all relevant demographic data will
be recorded.
Enrollment and randomization
Randomization will be performed independent of patient
recruitment or inclusion. To yield balanced yet unpredict-
able groups, we will use a block-randomization scheme in
varying blocks of four to six. This randomization list will
be provided to the hospital pharmacy for the preparation
of the blinded study drugs and otherwise concealed until
analysis of the study. Patient ID will be linked to container
numbers during the course of the study to warrant alloca-
tion concealment. For individual code breaking, we will
prepare a set of sequentially numbered sealed opaque en-
velopes that contain information about treatment alloca-
tion. At the end of the study all envelopes will be checked
to assess the absence of code breaking. All code breaks
will be documented in detail by the study investigators.
The randomization code will be broken in the case of any
serious adverse event (SAE) if knowledge of the study
drug is relevant to the treatment of the SAE. A consecu-
tive number will be assigned to any subject partaking in
the study as unique patient identifier code at the time of
inclusion.
Interventions
The treatment in arm one will be a weekly oral dose of
3 mg SIR (Rapamune®, Pfizer Ireland Pharmaceuticals,
Little Connell, Newbridge, Co. Kildare, Ireland), or placebo




• ADPKD, as confirmed by history, ultrasound, computed
tomography or magnetic resonance imaging
• 18 years of age, or older
• Baseline eGFR (4-variable MDRD equation) below
60 mL/min per 1.73 m2
• Negative serum pregnancy test prior to administration
of sirolimus and agreement to use contraception
throughout the study and for three months after
• Written informed consent
Exclusion
criteria
• Need for renal replacement therapy
• Pregnancy or lactation
• Plans to become pregnant in the near future
• Refusal to use sufficient contraception
• Proteinuria as defined as protein:creatinine ratio >1,000
or >1 g/d, respectively
• History of life-threatening complications of ADPKD
• Evidence of active systemic or localized major infection
• Evidence of infiltrate or consolidation on chest X-ray
• Use of any investigational drug or treatment up to
four weeks prior to enrolment and during the study
• Known allergy or hypersensitivity to sirolimus and its
derivatives
• Medication that will interfere with the CYP3A4/CYP3A5
system
• Total white blood cell count below or equal to 3,000/mm3
• Platelet count below or equal to 100,000/mm3
• Fasting triglycerides above or equal to 400 mg/dL
• Fasting total cholesterol above or equal to 300 mg/dL
• Concomitant glomerular diseases
• Psychiatric disorders and any condition that might
prevent full comprehension of the purposes and risks of
the study
• History of malignancy, with the exception of
adequately treated basal cell and squamous cell
carcinoma of the skin
• HIV positivity
ADPKD, autosomal-dominant polycystic kidney disease; CYP, cytochrome p-450;
eGFR, estimated glomerular filtration rate; HIV, human immunodeficiency virus;





















n = 34 n = 34
Figure 1 Patient flow of The Vienna RAP Study. ITT, intention to treat.
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powder in bovine empty hard gelatine capsules, Capsugel®,
Bornem, Belgium) equivalent in arm two (both blinded).
SIR oral loading doses of 6 mg are well tolerated in recipi-
ents of renal transplants. Pulsed intravenous admission of
the SIR analog temsirolimus at doses of 25 mg per week
was shown safe and effective in patients with renal cell car-
cinoma and hematological malignancies [10]. Since SIReffects mTOR inhibition at very low doses, we will admin-
ister a pulsed oral dose of 3 mg per week without the ne-
cessity to adjust trough levels. To minimize the risk of
accidental intoxication, SIR trough levels will be measured
at every visit. These measurements will only be accessible
for nominated nephrologists not otherwise involved in the
study, to protect blinding of the treating physicians and the
patients. The nominated nephrologists will notify the treat-
ing physicians in case of trough levels exceeding 20 ng/mL.Study regimens
See Figure 1 and Table 2 for the patient flow and trial
sequence.Dispensing, blinding, and monitoring of adherence
SIR will be provided by the manufacturer free of charge.
The placebo will be produced and all study medication
will be blinded by the pharmacy of the Vienna General
Hospital. The blinded medication will be dispensed in
sealed opaque containers, labeled with continuous study
IDs, by the principal investigator and his representatives.
Subject adherence will be monitored by interview at
study check-up visits.
Table 2 Trial sequence of The Vienna RAP Study
Timeline E W1 W2 M1 M6 M12 M18 M24
Visit V1 V2 V3 V4 V5 V6 V7 V7
General
Demography •
Clinical check • • • • •
Chemistry
Sodium • • • • • •
Potassium • • • • • •
Calcium • • • • • •
Phosphate • • • • • •
Creatinine • • • • • • • •
Urea • • • • • •
ASAT • • • • • •
ALAT • • • • • •
γ-GT • • • • • •
Lipids • • • • • •
Hba1c • • • • • •
Glucose • • • • • •
Pregnancy test • • • • • •
Sirolimus trough levela • • • • • • •
Hematology
Hemoglobin • • • • • •
Leucocytes • • • • • • • •
Platelets • • • • • • • •
Urine
24 hour proteinuria • • • • •
Creatinine clearance • • • • •
Protein/creatinine ratio • • • • • • • •





Vitamin D status • • • • •
PTH • • • • •
Nutritionist counseling •
ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; E,
enrolment; γ-GT, gamma glutamyl transferase; HbA1c, glycated hemoglobin;
HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency
virus; M, month; PTH, parathyroid hormone; V, visit W week; . aTo minimize the
risk of accidental intoxication, sirolimus trough levels will be measured at every
visit. These measurements will only be accessible for nominated nephrologists
not otherwise involved in the study to protect blinding of the treating physicians
and the patients. The nominated nephrologists will notify the treating physicians
in case of trough levels exceeding 20 ng/mL.
Table 3 Cytochrome p-450 inhibitors and inducers
CYP3A4 inhibitors: CYP3A4 inducers
• Bromocriptine • Carbamazepine
• Cimetidine • Rifabutin
• Clarithromycin • Rifampicin
• Danazol • Phenobarbital
• Fluconazole • Phenytoin
• Itraconazole • St John’s Wort (Hypericum perforatum)
• Protease inhibitors
• Telithromycin
To avoid potential intoxication or reduced efficacy by accidental co-administration
of these substances, every participant will be handed a list of the medication above
for emergency use.
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SIR is extensively metabolized by the hepatic and intes-
tinal isozyme cytochrome p-450 (CYP3A4). It is also asubstrate for the multidrug efflux pump P-glycoprotein
(P-gp), located in the small intestine. Curative or sup-
portive medication may be co-administered during the
trial without hesitation, with the exception of CYP3A4
inhibitors and inducers (Table 3), where alert monitoring
for side effects is necessary in the former.Standardized care
To ensure standardized care of disease progression modify-
ing factors, blood pressure will be targeted at <130/80 mmHg,
according to the Task Force for the Management of
Arterial Hypertension of the European Society of Hyper-
tension (ESH) and the European Society of Cardiology
(ESC) [11], in both treatment arms. Since the optimal
parathyroid hormone (PTH) levels in patients with
chronic kidney disease (CKD) stages three to five not on
dialysis are not known, the Kidney Disease Improving
Global Outcomes (KDIGO) Clinical Practice Guideline for
the Diagnosis, Evaluation, Prevention, and Treatment of
Chronic Kidney Disease - Mineral and Bone Disorder
(CKD-MBD) suggests that patients with levels of intact
PTH above the upper limit of normal of the assay are
first evaluated for hyperphosphatemia, hypocalcemia,
and vitamin D deficiency. Therapy should include the
reduction of dietary phosphate intake and the adminis-
tration of phosphate binders, calcium supplements,
and/or native vitamin D. In patients with CKD stages
three to five not on dialysis, in whom serum PTH is
progressively rising and remains persistently above the
upper limit of normal for the assay despite correction of
modifiable factors, treatment with calcitriol or vitamin
D analogues is suggested [12]. In participants of this
study target PTH levels are defined as 2- to 3-fold of the
normal range (15 to 65 pg/mL). The pH level as identi-
fied by venous blood sampling is defined as 7.35 to 7.43,
and bicarbonate target levels are defined as ≥20 mmol/L.
Also, every participant will receive dietary advice by a
nutritionist at the trial site at enrollment. Common side
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priate, see Table 4.Trial termination and post-trial care
The trial will be terminated per protocol when the last
patient finishes the trial period of 24 months. Any pa-
tient who wishes to discontinue the trial prematurely
may do so without providing a reason. All individuals
who discontinue the trial will re-enter the outpatient
program at the outpatient clinic of the Division of
Nephrology and Dialysis, Department of Medicine III,
Medical University of Vienna. Given the low dose treat-
ment and the small sample size, we do not plan a pre-
term stopping of the trial.Endpoints
The primary endpoint is a 50% reduction in the doub-
ling of serum creatinine, or initiation of dialysis, renal
transplantation, or death over a period of 2 years. A 1.5-
fold or lower increase in serum creatinine withoutTable 4 Commonly reported adverse reactions of
















• Impaired wound healing
• Increased serum creatinine








• Urinary tract infectioninitiation of dialysis, renal transplantation, or death over
2 years is considered a beneficial outcome; increases in
serum creatinine greater than 1.5 over 2 years or initi-
ation of dialysis, renal transplantation, or death are con-
sidered a non-beneficial outcome. Secondary endpoints
are safety, change in proteinuria (as indicated by albumin/
creatinine- and protein/creatinine ratio, respectively), and
creatinine clearance.Method of creatinine determination and estimation of
glomerular filtration rate
The serum creatinine values are analyzed by the enzym-
atic CREJ2 cobas® Jaffé Gen. 2 essay (Roche Diagnostics
GmbH, Mannheim, Germany) traceable to isotope dilu-
tion mass spectroscopy (IDMS). The eGFR will be calcu-
lated by the 4-variable MDRD equation [13]. Additional
estimates of the GFR will be made by the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) formula
[14]. The results of these two estimation methods will be
compared to analyze the concordance of performance.Measures to reduce influences of creatinine variability on
endpoints
To reduce the impact of fluctuations and variability of
serum creatinine on primary endpoint results, we will per-
form repeated measurements of serum creatinine (and es-
timations of GFR) at the end of the study at month 24,
and define the median value of four repeated measure-
ments (once every week over a period of four weeks) as
the creatinine value at the end of the study. To ensure
standardized conditions, we will give instructions to pa-
tients to maintain well hydrated, and to avoid excessive
consumption of meat and rigorous physical activity prior
to blood sampling.Source data, data collection, and documentation
The participants’ medical records are to be considered
the source data. The data for the statistical analysis will
be entered in electronic case report forms (eCRF), as
provided by the Center for Medical Statistics, Informat-
ics and Intelligent Systems (CeMSIIS) by the server-
based platform Clincase Software Structure for Clinical
Trials (Quadratek Data Solutions Ltd., London, UK).
Data will be entered only by the unique identifier code;
no patient names will be mentioned in the eCRF. The
study nurse or study coordinator will be authorized to
enter data. The principal investigator will have adminis-
trator rights to enter data and monitor data entry. Add-
itional personnel may be authorized for data entry by
the principal investigator, provided that the additional
staff are registered at the competent authorities with an
amendment.
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Any participant who becomes pregnant during the study
period and every female subject of child-bearing potential
who refuses to use sufficient contraceptives during the
trial will have to discontinue. Any participant who de-
velops de novo proteinuria, as defined as an elevation of
protein/albumin:creatinine ratio >200 and >30, respect-
ively, will have to discontinue the trial in case the protein:-
creatinine ratio exceeds the cut-off levels of >1,000 or
>1 g/d, respectively. Any participant who refuses to follow
the trial sequence will have to discontinue. Any patient
who discontinued the study will re-enter follow-up at the
outpatient clinic for routine check-up procedures. With-
drawn subjects will have to return the remaining study
medication.
Statistical methods
Categorical data will be presented as absolute and rela-
tive frequencies, and interval data will be presented as
mean and standard deviation or median and interquar-
tile range, as appropriate. Baseline data will be tabulated
and compared qualitatively and quantitatively. The pri-
mary analysis includes an intention-to-treat comparison
of the primary and secondary endpoints. The primary
endpoint is dichotomous and will be treated accordingly.
We assess the effect of the intervention by calculating a
relative risk with a 95% confidence interval. To test the
null hypothesis of no difference between the groups we
will use the Fisher’s exact test. For the secondary endpoint
change in proteinuria, as indicated by albumin/creatinine
and protein/creatinine ratio, we will compare the individ-
ual regression slopes from baseline to study end in these
variables between intervention and placebo group; we will
calculate differences and 95% confidence intervals. For hy-
pothesis testing, we will use an unpaired sample t test if a
normal distribution can be sensibly assumed, otherwise the
Mann-Whitney U test will be used. Adverse events (AE) will
be dichotomized and analyzed like the primary endpoint.
Secondary analysis will be performed if baseline differences
should be noted. In this case we will use multivariable re-
gression methods to adjust for such baseline differences. For
data management, range and consistency checks, and ana-
lyses we will use Excel (Microsoft, Redmond, WA, USA)
and Stata 11 (Stata Corp. College Station, TX, USA). No a
priori subgroup analyses are planned. An interim analysis is
not scheduled. To test for a possible dependency of GFR
on the effect of SIR in these patients we will perform an
explorative interaction analysis.
Number of subjects and level of significance
The calculation of the sample size is based on the results
of the most comprehensive follow-up of ADPKD patients
with advanced kidney disease. With a mean baseline cre-
atinine of 3 mg/dL, or a mean eGFR of 23 mL/min per1.73 m2, respectively, 40.5% of 142 patients showed a
doubling of serum creatinine or dialysis after a mean
follow-up of 2.3 years [15]. However, with less than 1.5
fold increase instead of 2 fold increase in creatinine we
used a stricter criterion for a favorable outcome, and
therefore set our expected outcome probability in the con-
trol group at 50%. Formally 31 patients in each group are
necessary to demonstrate a clinically meaningful reduc-
tion of 50 to 90% of the primary endpoint at an α = 0.05
with a power of 80%. To allow for loss to follow-up, we in-
crease this formal sample size by 10%. Therefore we plan
to include 34 patients per group or 68 patients overall into
our study. Generally a probability (P) value of less than
0.05 is considered statistically significant.
Procedure for accounting for missing, unused, and
spurious data
Every effort will be made to avoid missing data. The pri-
mary endpoint was designed in a way that missing data is
very unlikely. If data are missing, we will assess whether
data are missing at random or not by looking for system-
atic differences between patients with complete datasets
and those with missing values. If longitudinal data are
missing at random, we will use a mixed-model approach.
If missing not at random cannot be excluded, we will per-
form further sensitivity analyses following the principles
outlined in a recent guidance paper [16]. Spurious data
will be checked for transmission errors with the source
data and investigated by the clinical epidemiologist (HH).
To prevent event-triggered missing data, we will introduce
GFR substitutes for the three failure events initiation of
dialysis, renal transplantation, or death, with an adjusted
expected eGFR of 5 mL/min per 1.73 m2 [17].
Subjects to be included in the analyses
 Every individual who finishes the study will enter
the per protocol analysis.
 Every individual with a single exposure to the drug
will enter the intention-to-treat analysis.
 Every individual who declines to partake in the
study after randomization and before the first
exposure to the drug will be excluded of any
analysis.
Monitoring of cyst growth
Radiographic monitoring of cyst growth, especially mag-
netic resonance imaging cyst volumetry [18], has been
proposed as a marker of disease progression [19]. Lately
this concept has been challenged, since at least 50% of
the cysts are undetectable by magnetic resonance im-
aging due to their size being below the radiographic
and/or macroscopic threshold [20,21]. Therefore, we re-
frain from any form of radiographic kidney and cyst
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marker of therapeutic effects, since they directly repre-
sent the excretory kidney function. Retardation or ter-
mination of cyst growth inevitably results in a reduction
or the halt of the decline in eGFR.Assessment of safety
Safety of SIR and other mTOR inhibitors in this popula-
tion has been well established in numerous clinical trials.
The principal investigator and the sub-investigator have
conducted a pilot safety trial, Rapamycin in Advanced
Polycystic Kidney Disease - The Vienna RAP Safety Pilot
Study (EudraCT 2008-007980-18), approved by the
Ethics Committee at the Medical University of Vienna
(identifier 940/2009). In this trial 8 patients older than
18 years of age attending the outpatient department of
the Division of Nephrology and Dialysis, Department of
Medicine III at the Medical University of Vienna with
advanced ADPKD and an eGFR of 20 to 40 mL/min per
1.73 m2 received SIR at target trough levels of 4 to 8 ng/mL,
achieved no later than four weeks after commencement,
for six months. The primary endpoint was slope of
eGFR and proteinuria within six months of treatment
with SIR. Secondary endpoints included blood count,
lipids, and other known side effects of SIR. Since there
is no common clinically accepted dynamic cut-off level,
we calculated patient-specific dynamics and 95% confi-
dence intervals for regression slopes in a historic cohort.
Safety was not assumed if the mean decline in renal
function and the mean incline in proteinuria exceeded
the 95% confidence interval. With this pilot study we
proved our hypothesis that a single daily oral dose of
SIR in these patients does not lead to a eGFR-decline
lesser than −8.8 mL/min per 1.73 m2 within six months
(one-sided), and it does not lead to an incline of the
logarithm of the protein/creatinine ratio greater than
0.39 within six months (one-sided).Procedures for eliciting reports of and recording and
reporting of adverse events and intercurrent illnesses
AE will be classified into serious or minor, expected or
unexpected, study-related, possibly study-related, or not
study-related, and reported to the competent authority
by the investigator immediately after its discovery. Any
SAE, defined as any untoward medical occurrence that
at any dose results in death, is life-threatening, requires
inpatient hospitalization or prolongation of existing
hospitalization, results in persistent or significant dis-
ability or incapacity, is a congenital anomaly or birth
defect, or requires intervention to prevent permanent
impairment or damage, will be reported to the compe-
tent authority by the investigator immediately after its
discovery.Discussion
Currently there is no curative treatment for ADPKD. All
previously conducted clinical trials, with the exception
of one recently published randomized controlled pilot
study [21], could not demonstrate any clinically relevant
effect of mTOR inhibition on cyst growth or kidney
function (Interventions for retarding the progression of
autosomal dominant polycystic kidney disease (ADPKD):
A systematic review and meta-analysis. Bolignano D.,
51st ERA-EDTA Congress, Amsterdam, unpublished
data) With this study we will investigate the effects of
pulsed mTOR inhibition on kidney function. To the best
of our knowledge, this is the first trial to implement this
innovative administration of SIR in patients with ad-
vanced ADPKD.
Trial status
The first participant was enrolled on 28 April 2014 and
recruitment is ongoing. The last patient is expected to
be included in April 2017.
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